Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight decline in stock price and trading volume, with notable financing activities indicating investor behavior [1] - As of February 12, Weigao Blood Purification's financing balance is 116 million yuan, accounting for 7.24% of its market capitalization [1] - The company reported a total revenue of 2.736 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.45% [2] Group 2 - The net profit attributable to the parent company for the same period was 341 million yuan, representing a year-on-year increase of 7.92% [2] - The company has distributed a total of 65.8213 million yuan in dividends since its A-share listing [3] - As of September 30, the number of shareholders decreased by 20.95% to 24,800, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]
威高血净2月12日获融资买入602.23万元，融资余额1.16亿元